Item 2.02 Results of Operations and Financial Condition. On February 4, 2025, Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") issued a press release announcing its financial ...

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated ...

On March 10, the county legislature approved $6 million for the Pine Hills Land Authority to maintain campus security and infrastructure as revitalization plans unfold.

View Regeneron Pharmaceuticals, Inc. (REGN) current and estimated P/E ratio data provided by Seeking Alpha.

This was the stock's third consecutive day of losses.

This was the stock's second consecutive day of losses.

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S (NYSE: NVO) and Eli Lilly & Co. (NYSE: LLY ...

The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable options, 2 are puts, totaling $104,155, and 14 are calls, amounting to $721 ...

Long Island's six Regeneron Science Talent Search finalists are not yet out of high school and already, they've worked in some of the country's leading laboratories, helped to advance scientific ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...